Elekta (EKTA) Q1 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 24/25 earnings summary
23 Jan, 2026Executive summary
Net sales grew 1% in constant currencies, driven by strong installations in the U.S. and growth in the Americas, with a major $64 million order in Mexico; EMEA declined and China remained challenging due to anti-corruption measures.
Adjusted gross margin was 37.8%, down year-over-year due to inflation and reduced inventory revaluation, but improved sequentially by 120 basis points.
Adjusted EBIT margin declined to 7.4% year-over-year, mainly due to gross margin pressure and higher expenses; cost reduction initiatives have been launched.
Book-to-bill ratio improved to 1.10, supported by double-digit order growth and major wins.
Cost-reduction initiatives and new product launches are underway to improve profitability, targeting SEK 250 million annual savings by year-end.
Financial highlights
Group sales reached SEK 3,825M in Q1, with Americas up 16%, APAC up 3% (excluding China up 29%), and EMEA down 12%.
Service business grew 5% year-over-year; solution sales declined by 3% due to Europe and China.
Net income was SEK 71M; EPS at SEK 0.18 (0.62 last year); adjusted EPS SEK 0.41 (0.65 last year).
Cash flow after investments was negative SEK 891M, similar to last year; working capital as % of sales improved to -5% to -6%.
Rolling 12-month cash flow from operations was SEK 2.5B, up SEK 900M year-over-year; cash conversion at 83%.
Outlook and guidance
First half of 2024/25 expected to be weaker than last year; sales and profitability to pick up in the second half due to new product launches and productivity measures.
Full-year net sales expected to grow by mid-single digits with improved EBIT margin.
Long-term EBIT margin target set at 14% or higher, with margin expansion expected beyond 2024/25.
Latest events from Elekta
- Adjusted gross margin rose to 38.3% as restructuring costs and FX reduced net income.EKTA
Q3 20265 Mar 2026 - SEK 500m+ savings, job cuts, and innovation drive target growth in China and US.EKTA
Strategy update2 Feb 2026 - Sales up 5% year-over-year, but Q4 declined; margin recovery expected in H2 2024/25.EKTA
Q4 23/2431 Jan 2026 - Sales and margins declined, but new products and cost savings are set to boost performance.EKTA
Q2 24/2512 Jan 2026 - AI-driven adaptive radiotherapy and software boost growth, margins, and global adoption.EKTA
Investor update10 Jan 2026 - Record cash flow and European growth offset US and China weakness; margin guidance lowered.EKTA
Q3 24/2527 Dec 2025 - Margins improved, cash flow strengthened, and major cost-saving actions launched.EKTA
Q2 25/2626 Nov 2025 - Net sales up 3% in constant currency, margins down, net income up 50%, cash flow improved.EKTA
Q1 25/2623 Nov 2025 - Margin expansion, software growth, and profitable orders drive confidence in mid-term targets.EKTA
Investor update21 Nov 2025